ASKA Pharmaceutical Holdings Co.,Ltd. (4886.T)
JPY 2041.0
(-0.34%)
JPY 2041.0
(-0.34%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 24.16 Billion JPY | 2.93% |
| 2022 | 23.47 Billion JPY | 8.91% |
| 2021 | 21.55 Billion JPY | -1.0% |
| 2020 | 21.77 Billion JPY | -3.27% |
| 2019 | 22.5 Billion JPY | 31.58% |
| 2018 | 17.1 Billion JPY | 6.52% |
| 2017 | 16.06 Billion JPY | -6.19% |
| 2016 | 17.11 Billion JPY | 7.15% |
| 2015 | 15.97 Billion JPY | 2.06% |
| 2014 | 15.65 Billion JPY | -3.81% |
| 2013 | 16.27 Billion JPY | -0.91% |
| 2012 | 16.42 Billion JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 6.14 Billion JPY | -4.13% |
| 2024 Q1 | 6.41 Billion JPY | 5.83% |
| 2023 FY | 24.16 Billion JPY | 2.93% |
| 2023 Q1 | 5.75 Billion JPY | -6.39% |
| 2023 Q2 | 6.37 Billion JPY | 10.63% |
| 2023 Q3 | 5.97 Billion JPY | -6.23% |
| 2023 Q4 | 6.06 Billion JPY | 1.44% |
| 2022 Q4 | 6.15 Billion JPY | 4.24% |
| 2022 FY | 23.47 Billion JPY | 8.91% |
| 2022 Q3 | 5.9 Billion JPY | 1.15% |
| 2022 Q2 | 5.83 Billion JPY | 4.44% |
| 2022 Q1 | 5.58 Billion JPY | 0.87% |
| 2021 Q3 | 5.24 Billion JPY | -0.34% |
| 2021 FY | 21.55 Billion JPY | -1.0% |
| 2021 Q4 | 5.53 Billion JPY | 5.52% |
| 2021 Q2 | 5.26 Billion JPY | -4.25% |
| 2021 Q1 | 5.5 Billion JPY | 5.32% |
| 2020 Q3 | 6.29 Billion JPY | 8.68% |
| 2020 FY | 21.77 Billion JPY | -3.27% |
| 2020 Q1 | 5.19 Billion JPY | -16.01% |
| 2020 Q2 | 5.79 Billion JPY | 11.45% |
| 2020 Q4 | 5.22 Billion JPY | -17.04% |
| 2019 Q2 | 5.43 Billion JPY | -6.74% |
| 2019 Q3 | 5.82 Billion JPY | 7.12% |
| 2019 Q4 | 6.18 Billion JPY | 6.27% |
| 2019 Q1 | 5.83 Billion JPY | 23.57% |
| 2019 FY | 22.5 Billion JPY | 31.58% |
| 2018 FY | 17.1 Billion JPY | 6.52% |
| 2018 Q4 | 4.71 Billion JPY | 24.55% |
| 2018 Q3 | 3.78 Billion JPY | -17.99% |
| 2018 Q2 | 4.61 Billion JPY | 13.68% |
| 2018 Q1 | 4.06 Billion JPY | -2.14% |
| 2017 FY | 16.06 Billion JPY | -6.19% |
| 2017 Q2 | 3.94 Billion JPY | -1.13% |
| 2017 Q3 | 3.92 Billion JPY | -0.51% |
| 2017 Q4 | 4.15 Billion JPY | 5.92% |
| 2017 Q1 | 3.98 Billion JPY | -32.78% |
| 2016 FY | 17.11 Billion JPY | 7.15% |
| 2016 Q1 | 4.01 Billion JPY | 6.22% |
| 2016 Q2 | 3.98 Billion JPY | -0.6% |
| 2016 Q3 | 1.91 Billion JPY | -51.94% |
| 2016 Q4 | 5.92 Billion JPY | 209.39% |
| 2015 Q4 | 3.77 Billion JPY | -12.61% |
| 2015 Q3 | 4.32 Billion JPY | 15.66% |
| 2015 Q2 | 3.73 Billion JPY | -7.71% |
| 2015 Q1 | 4.04 Billion JPY | -6.47% |
| 2015 FY | 15.97 Billion JPY | 2.06% |
| 2014 Q3 | 3.59 Billion JPY | -5.02% |
| 2014 Q1 | 3.94 Billion JPY | -8.09% |
| 2014 FY | 15.65 Billion JPY | -3.81% |
| 2014 Q4 | 4.32 Billion JPY | 20.29% |
| 2014 Q2 | 3.78 Billion JPY | -3.88% |
| 2013 Q3 | 3.99 Billion JPY | -1.14% |
| 2013 Q1 | 3.95 Billion JPY | -16.0% |
| 2013 Q2 | 4.03 Billion JPY | 1.97% |
| 2013 FY | 16.27 Billion JPY | -0.91% |
| 2013 Q4 | 4.28 Billion JPY | 7.44% |
| 2012 FY | 16.42 Billion JPY | 0.0% |
| 2012 Q4 | 4.71 Billion JPY | 18.63% |
| 2012 Q2 | 3.8 Billion JPY | 0.0% |
| 2012 Q3 | 3.97 Billion JPY | 4.53% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 43.63 Billion JPY | 44.625% |
| Takeda Pharmaceutical Company Limited | 2618.18 Billion JPY | 99.077% |
| Sumitomo Pharma Co., Ltd. | 542.17 Billion JPY | 95.543% |
| Shionogi & Co., Ltd. | 197.62 Billion JPY | 87.772% |
| Wakamoto Pharmaceutical Co.,Ltd. | 3.73 Billion JPY | -546.753% |
| Nippon Shinyaku Co., Ltd. | 65.63 Billion JPY | 63.181% |
| Kaken Pharmaceutical Co., Ltd. | 29.02 Billion JPY | 16.747% |
| Eisai Co., Ltd. | 533.01 Billion JPY | 95.466% |
| Morishita Jintan Co., Ltd. | 5.28 Billion JPY | -357.497% |
| Hisamitsu Pharmaceutical Co., Inc. | 65.8 Billion JPY | 63.277% |
| Mochida Pharmaceutical Co., Ltd. | 46.26 Billion JPY | 47.771% |
| Fuso Pharmaceutical Industries,Ltd. | 11.55 Billion JPY | -109.166% |
| Nippon Chemiphar Co., Ltd. | 8.23 Billion JPY | -193.55% |
| Tsumura & Co. | 48.8 Billion JPY | 50.482% |
| Kissei Pharmaceutical Co., Ltd. | 33.32 Billion JPY | 27.485% |
| Torii Pharmaceutical Co., Ltd. | 19.53 Billion JPY | -23.688% |
| Towa Pharmaceutical Co., Ltd. | 63.73 Billion JPY | 62.086% |
| Fuji Pharma Co., Ltd. | 12.65 Billion JPY | -90.922% |
| Zeria Pharmaceutical Co., Ltd. | 40.46 Billion JPY | 40.281% |
| KYORIN Holdings, Inc. | 45.39 Billion JPY | 46.767% |
| Taiko Pharmaceutical Co.,Ltd. | 4.15 Billion JPY | -481.309% |
| Daito Pharmaceutical Co.,Ltd. | 5.94 Billion JPY | -306.476% |
| SymBio Pharmaceuticals Limited | 5.22 Billion JPY | -362.693% |
| MedRx Co., Ltd | 959 Million JPY | -2419.812% |
| Mizuho Medy Co.,Ltd. | 2.87 Billion JPY | -740.893% |
| Solasia Pharma K.K. | 1.47 Billion JPY | -1537.195% |
| Modalis Therapeutics Corporation | 2.37 Billion JPY | -919.334% |
| Sawai Group Holdings Co., Ltd. | 35.43 Billion JPY | 31.801% |
| Cyfuse Biomedical K.K. | 735.18 Million JPY | -3186.946% |
| Toho Holdings Co., Ltd. | 99.81 Billion JPY | 75.791% |
| Koa Shoji Holdings Co.,Ltd. | 2.25 Billion JPY | -970.533% |